{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:07:54Z","timestamp":1775153274002,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"DOI":"10.1186\/s13000-025-01630-5","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:49:43Z","timestamp":1742942983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A case of quadruple wild-type gastrointestinal stromal tumor with CDC42BPB::NTRK3 fusion and abundant lymphoid infiltration"],"prefix":"10.1186","volume":"20","author":[{"given":"Wentao","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaiyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingyong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"1630_CR1","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3748\/wjg.v12.i14.2223","volume":"12","author":"KH Chan","year":"2006","unstructured":"Chan KH, Chan CW, Chow WH, Kwan WK, Kong CK, Mak KF, Leung MY. Lau L. K. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol. 2006;12:2223\u20138.","journal-title":"World J Gastroenterol"},{"key":"1630_CR2","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.ejca.2005.09.009","volume":"41","author":"WG Goettsch","year":"2005","unstructured":"Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of Gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005;41:2868\u201372.","journal-title":"Eur J Cancer"},{"key":"1630_CR3","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/cncr.20862","volume":"103","author":"B Nilsson","year":"2005","unstructured":"Nilsson B, B\u00fcmming P, Meis-Kindblom JM, Od\u00e9n A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era\u2013a population-based study in Western Sweden. Cancer. 2005;103:821\u20139.","journal-title":"Cancer"},{"key":"1630_CR4","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","volume":"369","author":"BP Rubin","year":"2007","unstructured":"Rubin BP, Heinrich MC. Corless C. L. Gastrointestinal stromal tumour. Lancet. 2007;369:1731\u201341.","journal-title":"Lancet"},{"key":"1630_CR5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. PDGFRA activating mutations in Gastrointestinal stromal tumors. Science. 2003;299:708\u201310.","journal-title":"Science"},{"key":"1630_CR6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JCO.2016.68.6733","volume":"35","author":"CB Weldon","year":"2017","unstructured":"Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, Pappo AS, Schiffman JD, Wright J, Trent JC, et al. Surgical management of Wild-Type Gastrointestinal stromal tumors: A report from the National institutes of health pediatric and wildtype GIST clinic. J Clin Oncol. 2017;35:523\u201328.","journal-title":"J Clin Oncol"},{"key":"1630_CR7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cam4.325","volume":"4","author":"MA Pantaleo","year":"2015","unstructured":"Pantaleo MA, Nannini M, Corless CL, Heinrich MC. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med. 2015;4:101\u20133.","journal-title":"Cancer Med"},{"key":"1630_CR8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12967-016-1075-6","volume":"14","author":"E Shi","year":"2016","unstructured":"Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL, Hong D, Fero KE, Murphy JD, et al. FGFR1 and NTRK3 actionable alterations in Wild-Type Gastrointestinal stromal tumors. J Transl Med. 2016;14:339.","journal-title":"J Transl Med"},{"key":"1630_CR9","doi-asserted-by":"crossref","first-page":"e1881","DOI":"10.1002\/mgg3.1881","volume":"10","author":"W Huang","year":"2022","unstructured":"Huang W, Yuan W, Ren L, Xu C, Luo R, Zhou Y, Lu W, Hao Q, Xu M, Hou Y. A novel fusion between CDC42BPB and ALK in a patient with quadruple wild-type Gastrointestinal stromal tumor. Mol Genet Genomic Med. 2022;10:e1881.","journal-title":"Mol Genet Genomic Med"},{"key":"1630_CR10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","volume":"72","author":"EJ Huang","year":"2003","unstructured":"Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609\u201342.","journal-title":"Annu Rev Biochem"},{"key":"1630_CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","volume":"5","author":"CB Westphalen","year":"2021","unstructured":"Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, Jin DX, Newberg JY, Fabrizio D, Veronese L, et al. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5:69.","journal-title":"NPJ Precis Oncol"},{"key":"1630_CR12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/300539a0","volume":"300","author":"S Pulciani","year":"1982","unstructured":"Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M. Oncogenes in solid human tumours. Nature. 1982;300:539\u201342.","journal-title":"Nature"},{"key":"1630_CR13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0298-184","volume":"18","author":"SR Knezevich","year":"1998","unstructured":"Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen P. H. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184\u20137.","journal-title":"Nat Genet"},{"key":"1630_CR14","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","volume":"1","author":"A Amatu","year":"2016","unstructured":"Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1:e000023.","journal-title":"ESMO Open"},{"key":"1630_CR15","doi-asserted-by":"crossref","first-page":"101202","DOI":"10.1016\/j.esmoop.2023.101202","volume":"8","author":"A Dufresne","year":"2023","unstructured":"Dufresne A, Pissaloux D, Ngo C, Penel N, Le Cesne A, Macagno N, Vanacker H, H\u00e9non C, Jean-Denis M, Rughoo K, et al. Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors. ESMO Open. 2023;8:101202.","journal-title":"ESMO Open"},{"key":"1630_CR16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12029-020-00423-x","volume":"52","author":"R D\u2019Alpino Peixoto","year":"2021","unstructured":"D\u2019Alpino Peixoto R, Medeiros BA, Cronemberger EH. Resected High-Risk rectal GIST harboring NTRK1 fusion: a case report and review of the literature. J Gastrointest Cancer. 2021;52:316\u201319.","journal-title":"J Gastrointest Cancer"},{"key":"1630_CR17","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","volume":"39","author":"H Joensuu","year":"2008","unstructured":"Joensuu H. Risk stratification of patients diagnosed with Gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411\u20139.","journal-title":"Hum Pathol"},{"key":"1630_CR18","unstructured":"WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon (Franee): International Agency for Research on Cancer; 2020:220. (WHO classification of tumours series, 5th ed.; vol. 3)."},{"key":"1630_CR19","doi-asserted-by":"crossref","unstructured":"Gol\u010di\u0107 M, Jones RL, Huang P, Napolitano A. Evaluation of systemic treatment options for Gastrointestinal stromal tumours. Cancers (Basel). 2023;15.","DOI":"10.3390\/cancers15164081"},{"key":"1630_CR20","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41598-024-51211-7","volume":"14","author":"K Sasa","year":"2024","unstructured":"Sasa K, Son R, Oguchi A, Ashizawa K, Hasegawa N, Kubota D, Suehara Y, Takagi T, Okubo T, Akaike K, et al. NTRK2 expression in Gastrointestinal stromal tumors with a special emphasis on the clinicopathological and prognostic impacts. Sci Rep. 2024;14:768.","journal-title":"Sci Rep"},{"key":"1630_CR21","doi-asserted-by":"crossref","unstructured":"Machado I, Claramunt-Alonso R, Lavernia J, Romero I, Barrios M, Safont MJ, Santonja N, L\u00f3pez-Guerrero NL J. A. and, Llombart-Bosch A. ETV6::NTRK3 Fusion-Positive Wild-Type Gastrointestinal stromal tumor (GIST) with abundant lymphoid infiltration (TILs and tertiary lymphoid Structures): A Report on a New Case with Therapeutic Implications and a Literature Review. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms25073707"},{"key":"1630_CR22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41379-020-0623-z","volume":"34","author":"MA Atiq","year":"2021","unstructured":"Atiq MA, Davis JL, Hornick JL, Dickson BC, Fletcher CDM, Fletcher JA, Folpe AL, Mari\u00f1o-Enr\u00edquez A. Mesenchymal tumors of the Gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from Gastrointestinal stromal tumor (GIST). Mod Pathol. 2021;34:95\u2013103.","journal-title":"Mod Pathol"},{"key":"1630_CR23","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","volume":"79","author":"JP Solomon","year":"2019","unstructured":"Solomon JP, Hechtman JF. Detection of NTRK fusions: merits and limitations of current diagnostic platforms. Cancer Res. 2019;79:3163\u201368.","journal-title":"Cancer Res"},{"key":"1630_CR24","doi-asserted-by":"crossref","unstructured":"Cao Z, Li J, Sun L, Xu Z, Ke Y, Shao B, Guo Y, Sun Y. GISTs with NTRK gene fusions: A clinicopathological, immunophenotypic, and molecular study. Cancers (Basel). 2022;15.","DOI":"10.3390\/cancers15010105"},{"key":"1630_CR25","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12253-019-00685-2","volume":"26","author":"D Wong","year":"2020","unstructured":"Wong D, Yip S, Sorensen PH. Methods for identifying patients with Tropomyosin receptor kinase (TRK) fusion cancer. Pathol Oncol Res. 2020;26:1385\u201399.","journal-title":"Pathol Oncol Res"},{"key":"1630_CR26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","volume":"21","author":"SJ Hsiao","year":"2019","unstructured":"Hsiao SJ, Zehir A, Sireci AN, Aisner DL. Detection of tumor NTRK gene fusions to identify patients who May benefit from tyrosine kinase (TRK) inhibitor therapy. J Mol Diagn. 2019;21:553\u201371.","journal-title":"J Mol Diagn"},{"key":"1630_CR27","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","volume":"30","author":"C Marchi\u00f2","year":"2019","unstructured":"Marchi\u00f2 C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, L\u00f3pez-Rios F, Douillard JY, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30:1417\u201327.","journal-title":"Ann Oncol"},{"key":"1630_CR28","unstructured":"Chinese Society of Clinical Oncology. Gastrointestinal stromal tumors. Beijing: People\u2019s medical publishing house. 2024: 9\u201310."},{"key":"1630_CR29","first-page":"201","volume":"79","author":"LJ Scott","year":"2019","unstructured":"Scott LJ, Larotrectinib. First Global Approval Drugs. 2019;79:201\u201306.","journal-title":"First Global Approval Drugs"},{"key":"1630_CR30","first-page":"1477","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Keam SJ, Entrectinib. First Global Approval Drugs. 2019;79:1477\u201383.","journal-title":"First Global Approval Drugs"},{"key":"1630_CR31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340.","journal-title":"Lancet Oncol"},{"key":"1630_CR32","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.annonc.2020.08.2232","volume":"31","author":"GD Demetri","year":"2020","unstructured":"Demetri GD, Antonescu CR, Bjerkehagen B, Bov\u00e9e Jvmg BK, Chac\u00f3n M, Dei Tos AP, Desai J, Fletcher JA, Gelderblom H, et al. Diagnosis and management of Tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the world sarcoma network. Ann Oncol. 2020;31:1506\u201317.","journal-title":"Ann Oncol"},{"key":"1630_CR33","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley L. C. AKT\/PKB signaling: navigating downstream. Cell. 2007;129:1261\u201374.","journal-title":"Cell"},{"key":"1630_CR34","doi-asserted-by":"crossref","unstructured":"Shkolyar E, Zhao Q, Mach KE, Teslovich NC, Lee TJ, Cox S, Skinner EC, Lu Y, Liao JC. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging. Urol Oncol. 2021;39:497.e9-97.e15.","DOI":"10.1016\/j.urolonc.2021.02.011"},{"key":"1630_CR35","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1016\/j.ymthe.2024.07.021","volume":"32","author":"RP Deshpande","year":"2024","unstructured":"Deshpande RP, Wu K, Wu SY, Tyagi A, Smith EC, Hunting J, Ruiz J, Li W, Watabe K. Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint Blockade in breast cancer. Mol Ther. 2024;32:3669\u201382.","journal-title":"Mol Ther"},{"key":"1630_CR36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13000-021-01133-z","volume":"16","author":"F Wagner","year":"2021","unstructured":"Wagner F, Greim R, Krebs K, Luebben F, Dimmler A. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report. Diagn Pathol. 2021;16:73.","journal-title":"Diagn Pathol"},{"key":"1630_CR37","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/PAI.0000000000000933","volume":"29","author":"M Castillon","year":"2021","unstructured":"Castillon M, Kammerer-Jacquet SF, Cariou M, Costa S, Conq G, Samaison L, Douet-Guilbert N, Marcorelles P, Doucet L, Uguen A. Fluorescent in situ hybridization must be preferred to pan-TRK immunohistochemistry to diagnose NTRK3-rearranged Gastrointestinal stromal tumors (GIST). Appl Immunohistochem Mol Morphol. 2021;29:626\u201334.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1630_CR38","doi-asserted-by":"crossref","unstructured":"Lee JH, Shin SJ, Choe EA, Kim J, Hyung WJ, Kim HS, Jung M, Beom SH, Kim TI, Ahn JB et al. Tropomyosin-Related kinase fusions in Gastrointestinal stromal tumors. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14112659"},{"key":"1630_CR39","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.asjsur.2023.04.084","volume":"46","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yin X, Zhang B, Chen Z. Wild-type Gastrointestinal stromal tumors with NTRK gene fusions: A clinicopathological study. Asian J Surg. 2023;46:4435\u201336.","journal-title":"Asian J Surg"},{"key":"1630_CR40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/path.4677","volume":"238","author":"M Brenca","year":"2016","unstructured":"Brenca M, Rossi S, Polano M, Gasparotto D, Zanatta L, Racanelli D, Valori L, Lamon S. Dei Tos A. P. and maestro R. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol. 2016;238:543\u20139.","journal-title":"J Pathol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01630-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T22:51:26Z","timestamp":1742943086000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-025-01630-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01630-5","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participant in our study provided signed informed consent. This study was approved by the ethics committee of the Zhongshan Hospital, Fudan University, and the IRB is B2022-532R2.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}